Showing 4401-4410 of 7278 results for "".
- Meet the ASDSA 2017 State Patient Safety Hero Award Honoreeshttps://practicaldermatology.com/news/meet-the-asdsa-2017-state-patient-safety-hero-award-honorees/2458020/The American Society for Dermatologic Surgery Association (ASDSA) honored the recipient
- Women of Color May Be Disproportionately Exposed to Beauty Product Chemicalshttps://practicaldermatology.com/news/women-of-color-may-be-disproportionately-exposed-to-beauty-product-chemicals/2458087/Women with skin of color have higher levels of beauty-product related chemicals in their bodies compared to white women, according to a commentary published in the American Journal of Obstetrics and Gynecology.<
- Valeant's Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AADhttps://practicaldermatology.com/news/valeants-newly-minted-orthodermatologic-division-makes-a-big-splash-at-summer-aad/2458105/It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch Siliq (brodalumab) for psoriasis and announce their new name change. Dermwire
- Common Soap Ingredient May Alter Skin's Wettabilityhttps://practicaldermatology.com/news/common-soap-ingredient-may-alter-skins-wettability/2458139/New research suggests that it is possible to alter the wettability of your skin using an ingredient commonly found in cosmetic cleaners. In a recent study, Guy German, PhD, an assistant professor of biomedical engineering at Binghamton University, State University of New York, along with
- PsA Patients Failing Anti-TNF Drugs May Do Well on Taltzhttps://practicaldermatology.com/news/psa-patients-who-fail-anti-tnf-drugs-may-do-well-on-taltz/2458154/New data show that Taltz (ixekizumab) improved the signs and symptoms of active psoriatic arthritis (PsA) in patients who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated. Eli Lilly has filed a supple
- Rare Disease Breakthrough? New Treatment May Reduce Blistering in EBShttps://practicaldermatology.com/news/rare-disease-breakthrough-new-treatment-may-reduce-blistering-in-ebs/2458255/In a possible breakthrough in the treatment of epidermolysis bullosa simplex (EBS), Diacerein 1% ointment reduced blistering in patients with this rare genetic connective tissue disorder. The new findings were presented in a late-breaker session at the American Academy of Dermatology Annu
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill
- Skin Diseases Remain Major Cause of Disabilityhttps://practicaldermatology.com/news/skin-diseases-remain-major-cause-of-disability/2458267/Skin diseases are the fourth leading cause of disability worldwide, according to the Global Burden of Disease 2013 Study which appears online in JAMA Dermatology. For the study, researchers estimate
- Certain Lifestyle Choices May Trump Genes When it Comes to Youthful Looking Skinhttps://practicaldermatology.com/news/certain-lifestyle-choices-may-trump-genes-when-it-comes-to-youthful-looking-skin/2458313/Nurture has a larger effect on exceptionally youthful skin appearance than nature, according to a new study by Olay done in collaboration with personal genetics company 23andMe. Specifically, sunscreen usage and
- Novan: SB414 Inhibited IL-17 in Psoriasis Mouse Modelhttps://practicaldermatology.com/news/novan-sb414-inhibited-il-17-in-psoriasis-mouse-model/2458374/Novan, Inc. has announced preclinical data showing that its nitric oxide-releasing product candidate SB414 significantly (p<0.05) reduced composite psoriasis scores, which consist of erythema and plaque scores, and pro-inflammatory cytokines, including interleukin-17, or IL-17, in a